Anti Asthma Drugs Market Research Report – Global Forecast to 2027

Anti-Asthma Drugs Market Information, by     Type of Asthma (Allergic (Extrinsic) and Non-Allergic (Intrinsic) Asthma), by Asthma Trigger Type (Child-Onset Asthma, Adult-Onset Asthma, Exercise-Induced Asthma, Cough-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma (Severe Asthma)), by Drug Class (Bronchodilators (Beta Agonists, Anti-Cholinergics, Xanthines), Leukotriene Antagonists, Mast Cell Stabilizers,  Corticosteroids, Monoclonal Antibody), by Therapy (Reliever Treatment and Maintenance Treatment) and by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous)- Global Forecast to 2027

ID: MRFR/Pharma/1736-HCR | February 2021 | Region: Global | 85 pages

Market Synopsis of anti-asthma drugs market:


Market Scenario:


Asthma is a chronic lung disease characterized by hyper responsiveness of tracheobronchial smooth muscle to stimuli, resulting in narrowing and inflammation of air tubes, accompanied by increased secretion, swelling and build-up of tissue fluid. Symptoms include tight chest, wheezing, cough and may be limitation of activity due to difficulty in breathing.


Approximately, 300 million people suffer from asthma in 2015 and the figures are mounting which is blamed on increased pollution and unhealthy lifestyles. This has bloated the market to around USD 18.9 billion as of 2015 which is expected to reach USD 28.3 billion as of 2022, resulting in a CAGR of 5.94%. The factors favoring the growth of the market are growing awareness of the benefits of modern drug therapy, strong pipeline of anti-asthma drugs with some novel molecules, growth in patients due to increasing pollution and great potential of biologics which is anticipated to dominate the future market etc.


The constraining factors are loss of patents of leading brands, such as Advair and Symbicort, increasing fragmentation of markets and generic penetration. It is heartening to note that we anticipate that the growth factors will overwhelm the constraints and the market may take a strong growth due to commercialization of the biologics segment.


Study Objectives anti-asthma drugs market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global anti-asthma drugs market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the anti-asthma drugs market segments and sub-segments with respect to four main geographies and their countries - Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the anti-asthma drugs market for segments by type (allergic (extrinsic) and non-allergic (intrinsic)), by trigger type (child-onset, adult-onset, exercise-induced, cough-induced, occupational, nocturnal, steroid-resistant), by therapy (reliever treatment and maintenance treatment), by drug class (Bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, monoclonal antibody) and by route of administration (oral, inhaled, intravenous, subcutaneous)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.


Anti-asthma drugs market, by Region 2015 & 2022 (USD million)Global Anti Asthma Drugs Market


 


Intended Audience:



  • Global anti-asthma drugs manufacturers

  • Global anti-asthma drugs suppliers

  • Research and development Laboratories

  • Market Research and Consulting Service Providers


Key Players for anti-asthma drugs market:


GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.


Segments:


Anti-asthma drugs market has been segmented on the basis of by type, trigger, therapy, drug class and by route of administration.


Regional Analysis of anti-asthma drugs market:


Globally North America is the largest market for anti-asthma drugs. Europe is the second-largest market for anti-asthma drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future.


The report for Anti-Asthma Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 28.3 Billion
  CAGR   5.94% (2016-2022)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, trigger, therapy, drug class and by route of administration
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.
  Key Market Opportunities   increasing pollution and great potential of biologics which is anticipated to dominate the future
  Key Market Drivers

  • Growing awareness of the benefits of modern drug therapy
  • Strong pipeline of anti-asthma drugs with some novel molecules


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Anti asthma drugs market is valued at USD 28.3 billion by 2022.

    Anti asthma drugs market can expand at 5.94% CAGR from 2015 to 2022.

    Anti asthma drugs market is driven by large number of asthma patients, advantages of modern drug therapy, and potential of biologics.

    Patent expiry of blockbuster drugs is one of the biggest challenges faced by the global anti asthma drugs market.

    The Americas can dominate the global anti asthma drugs market till 2022.

    Novartis International AG, Teva Pharmaceutical Industries, AstraZeneca plc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim, GlaxoSmithKline plc., Merck & Co., Inc., and Sunovion Pharmaceuticals Inc. are notable players of the global anti asthma drugs market.

    Table of Contents

    1 Introduction

    1.1 Definition

    1.2 Scope of Study

    1.3 Research Objective

    1.4 Assumptions & Limitations

    1.5 Market Structure

    2 Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research

    3 Market Dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Challenges

    3.5 Macroeconomic Indicators

    4 Market Factor Analysis

    4.1 Porter’s five forces model

    4.1.1 Bargaining Power of suppliers

    4.1.2 Bargaining Power of Customer

    4.1.3 Intensity of Competitor’s

    4.1.4 Threat of New Entrants

    5 Global anti-asthma drugs market, by type

    5.1 Introduction

    5.1.1 Allergic (extrinsic)

    5.1.2 Non-allergic (intrinsic) asthma

    6 Global anti-asthma drugs market, by trigger

    6.1 Introduction

    6.1.1 Child-onset asthma

    6.1.2 Adult-onset asthma

    6.1.3 Exercise-induced asthma

    6.1.4 Cough-induced asthma

    6.1.5 Occupational asthma

    6.1.6 Nocturnal asthma

    6.1.7 Steroid-resistant asthma

    7 Global anti-asthma drugs market, by drug class

    7.1 Introduction

    7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)

    7.1.2 Leukotriene antagonists

    7.1.3 Mast cell stabilizers

    7.1.4 Corticosteroids

    7.1.5 Monoclonal antibody

    7.1.6 Others

    8 Global anti-asthma drugs market, by therapy

    8.1 Introduction

    8.1.1 Preventive

    8.1.2 Curative

    9 Global anti-asthma drugs market, by route of administration

    9.1 Introduction

    9.1.1 Oral

    9.1.2 Inhaled

    9.1.3 Intravenous

    9.1.4 Subcutaneous

    10 Global anti-asthma drugs market, by Regions

    10.1 Introduction

    10.1.1 Americas

    10.1.1.1 North America

    10.1.1.2 South America

    10.1.2 Europe

    10.1.2.1 Germany

    10.1.2.2 France

    10.1.2.3 UK

    10.1.2.4 Italy

    10.1.2.5 Spain

    10.1.2.6 Rest of Europe

    10.1.3 Asia Pacific

    10.1.3.1 Japan

    10.1.3.2 China

    10.1.3.3 India

    10.1.3.4 Republic of Korea

    10.1.3.5 Rest of Asia Pacific

    10.1.4 Middle East & Africa

    11 Company Landscape

    11.1 Introduction

    11.1.1 Mergers Acquisitions

    11.1.2 Collaborations

    11.1.3 Release/New Product Launch

    11.1.4 Other (Expansion, Updates, Partnership)

    12 Company Profile

    12.1 GlaxoSmithKline plc.

    12.1.1 Company Overview

    12.1.2 Product/Business Segment Overview

    12.1.3 Financials

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Merck & Co., Inc.

    12.2.1 Overview

    12.2.2 Product/Business Segment Overview

    12.2.3 Financials

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 AstraZeneca plc.

    12.3.1 Overview

    12.3.2 Product/Business Segment Overview

    12.3.3 Financials

    12.3.4 Key Developments

    12.3.5 SWOT Analysis

    12.4 F. Hoffmann-La Roche Ltd

    12.4.1 Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financials

    12.4.4 Key Developments

    12.4.5 SWOT Analysis

    12.5 Teva Pharmaceutical Industries

    12.5.1 Overview

    12.5.2 Product/Business Segment Overview

    12.5.3 Financials

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Novartis International AG

    12.6.1 Overview

    12.6.2 Product/Business Segment Overview

    12.6.3 Financials

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Boehringer Ingelheim

    12.7.1 Overview

    12.7.2 Product/Business Segment Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Sunovion Pharmaceuticals Inc.

    12.8.1 Overview

    12.8.2 Product/Business Segment Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    13 Others

    14 Appendix

    List of Tables

    TABLE 1 GLOBAL ANTI-ASTHMA DRUGS MARKET, 2020-2027 (USD MILLION)

    TABLE 2 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)